What is the most recent earnings date for ATHA stock?
ATHIRA PHARMA INC (ATHA) last reported earnings on 11/6/2025.
NASDAQ:ATHA • US04746L2034
Past quarterly earnings results for ATHIRA PHARMA INC (ATHA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -1.68 | -1.24 | -35.00% | 77.60% | - | - | ||
| Q2 2025 | -1.80 | -1.84 | 1.96% | 74.29% | - | - | ||
| Q1 2025 | -2.30 | -2.45 | 6.05% | 66.67% | - | - | ||
| Q4 2024 | -3.90 | -4.49 | 13.23% | 45.07% | - | - | ||
| Q3 2024 | -7.50 | -7.20 | -4.12% | 13.79% | - | - | ||
| Q2 2024 | -7.00 | -7.52 | 6.86% | 10.26% | - | - | ||
| Q1 2024 | -6.90 | -8.06 | 14.42% | 5.48% | - | - | ||
| Q4 2023 | -7.10 | -9.79 | 27.47% | -33.96% | - | - | ||
| Q3 2023 | -8.70 | -8.30 | -4.78% | -64.15% | - | - | ||
| Q2 2023 | -7.80 | -7.99 | 2.36% | -20.00% | - | - | ||
| Q1 2023 | -7.30 | -6.36 | -14.69% | -30.36% | - | - | ||
| Q4 2022 | -5.30 | -6.83 | 22.45% | -17.78% | - | - | ||
| Q3 2022 | -5.30 | -6.46 | 17.96% | -26.19% | - | - | ||
| Q2 2022 | -6.50 | -6.51 | 0.17% | -71.05% | - | - | ||
| Q1 2022 | -5.60 | -5.61 | 0.18% | -124.00% | - | - | ||
| Q4 2021 | -4.50 | -5.51 | 18.30% | -87.50% | - | - | ||
| Q3 2021 | -4.20 | -5.07 | 17.09% | 62.50% | - | - | ||
| Q2 2021 | -3.80 | -3.52 | -7.99% | - | - | - | ||
| Q1 2021 | -2.50 | -3.09 | 18.98% | - | - | - | ||
| Q4 2020 | -2.40 | -4.05 | 40.68% | - | - | - | ||
| Q3 2020 | -11.20 | -2.55 | -339.22% | - | 68.003K | -100.00% | - | |
| Q2 2020 | - | - | - | - |
Notes
ATHIRA PHARMA INC (ATHA) last reported earnings on 11/6/2025.
ATHIRA PHARMA INC (ATHA) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ATHIRA PHARMA INC (ATHA) has beaten EPS estimates in 3 out of 4 releases.